longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

EXEL: Q2 2026 revenues rose 10% year-over-year, with Zanza's CRC NDA under review and guidance trimmed

Quartr
Aug 5, 2026 at 11:25 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Q2 2026 revenues grew to $629M, with CABO franchise up 10% year-over-year and global revenues up 13%. Zanza's CRC NDA is under review, with multiple pivotal trials advancing and a robust pipeline supporting long-term growth. Guidance was lowered due to a slower NET ramp.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Q2 2026 revenues grew to $629M, with CABO franchise up 10% year-over-year and global revenues up 13%. Zanza's CRC NDA is under review, with multiple pivotal trials advancing and a robust pipeline supporting long-term growth. Guidance was lowered due to a slower NET ramp.

Based on

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Login to unlock417characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Exelixis

Exelixis

EXEL.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI